Literature DB >> 27375159

Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies.

Nischala Ammannagari1, Kimberly Celotto1, Vishala Neppalli2, Kelvin Lee1, Sarah A Holstein3.   

Abstract

Entities:  

Keywords:  AMM; Central nervous system involvement; Extramedullary myeloma; Immunomodulatory drug; Proteasome inhibitor

Mesh：

Year:  2016        PMID： 27375159     DOI： 10.1016/j.clml.2016.06.008

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  4 in total

1.  Morphological Transformation of Myeloma Cells into Multilobated Plasma Cell Nuclei within 7 Days in a Case of Secondary Plasma Cell Leukemia That Finally Transformed as Anaplastic Myeloma.

Authors:  Akihito Fujimi; Yasuhiro Nagamachi; Naofumi Yamauchi; Yuji Kanisawa
Journal:  Case Rep Hematol       Date:  2017-12-21

2.  Anaplastic multiple myeloma with MYC rearrangement.

Authors:  Satoshi Ichikawa; Noriko Fukuhara; Ko Hashimoto; Fumiyoshi Fujishima; Ryo Ichinohasama; Hideo Harigae
Journal:  Leuk Res Rep       Date:  2021-12-27

3.  Anaplastic Multiple Myeloma: Case Series and Literature Review.

Authors:  Jian Wu; Emily Chu; Cristiana Costa Chase; Taewoong Choi; Cristina Gasparetto; Ken Young; Yubin Kang
Journal:  Asploro J Biomed Clin Case Rep       Date:  2022-01-15

4.  Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.

Authors:  Masuho Saburi; Masao Ogata; Yasuhiro Soga; Yoshiyuki Kondo; Ryo Kurimoto; Kazuhito Itani; Kazuhiro Kohno; Hiroki Uchida; Toshiyuki Nakayama
Journal:  J Clin Exp Hematop       Date:  2020
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.